ArticleBritish journal of cancer2026
VISTA drives tumour-intrinsic proliferation in mesothelioma cells.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMesothelioma is a therapeutic challenge because current therapies have limited efficacy. In this study, we investigated the role of the immune checkpoint molecule V-domain Ig suppressor of T cell activation (VISTA) in mesothelioma cells.
methodsThe effect of VISTA expression on cell proliferation was analysed using mesothelioma cell lines and a mouse xenograft model. To investigate the underlying mechanisms, we performed immunoprecipitation-mass spectrometry and RNA-seq analysis to identify VISTA-associated proteins and downstream transcriptional changes.
resultsAnalysis of The Cancer Genome Atlas (TCGA) dataset revealed that VISTA and B7-H3 were highly expressed in mesothelioma cells; their expression patterns were positively correlated with those of genes highly expressed in epithelioid and sarcomatoid cells, respectively. Functional studies revealed that VISTA overexpression enhanced proliferation of mesothelioma cell lines, whereas VISTA knockdown markedly suppressed tumour growth in vitro and in vivo. Proteomic profiling revealed interactions between VISTA, cell adhesion molecules and intracellular signalling proteins such as receptor-interacting serine/threonine-protein kinase 1 (RIPK1), whereas RNA sequencing revealed enrichment of TNF signalling, and functional analyses demonstrated enhanced AKT phosphorylation.
conclusionsThese findings indicate that VISTA promotes mesothelioma cell proliferation through tumour-intrinsic signalling independent of immune modulation. VISTA is a promising subtype-specific therapeutic target for mesothelioma.
Identifiers
42806022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.